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Abstract: 
Aims: We sought to investigate the prognostic impact of co-morbid burden as defined by the 
Charlson comorbidity index (CCI) in patients with a range of prevalent cardiovascular 
diseases. 
 
Methods & Results: We searched MEDLINE and EMBASE to identify studies that 
evaluated the impact of CCI on mortality in patients with cardiovascular disease. A random 
effects meta-analysis was undertaken to evaluate the impact of CCI on mortality in patients 
with coronary heart disease (CHD), heart failure (HF) and cerebrovascular accident (CVA). 
A total of 11 studies of acute coronary syndrome (ACS), 2 stable coronary disease, 5 
percutaneous coronary intervention (PCI), 13 HF and 4 CVA met the inclusion criteria. An 
increase in CCI score per point was significantly associated with a greater risk of mortality in 
patients with ACS (pooled relative risk ratio (RR) 1.33 95%CI 1.15-1.54), PCI (RR 1.21 95% 
CI1.12-1.31) stable coronary artery disease (RR 1.38 95%CI 1.29-1.48) and HF (RR1.21 
95%CI 1.13-1.29), but not CVA. A CCI score >2 significantly increased the risk of mortality 
in ACS (RR 2.52 95% CI 1.58-4.04), PCI (3.36 95%CI 2.14-5.29), HF (RR 1.76 95%CI 
1.65-1.87) and CVA (RR 3.80 95%CI 1.20-12.01). 
 
Conclusion: Increasing co-morbid burden as defined by CCI is associated with a significant 
increase in risk of mortality in patients with underlying CHD, HF and CVA. CCI provides a 
simple way of predicting adverse outcomes in patients with CV disease and should be 
incorporated into decision-making processes when counseling patients. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 Cardiovascular disease (CVD) is a major cause of morbidity and mortality, 
accounting for 30% of all cause mortality worldwide1. Given the incidence of CVD and co-
morbidity burden increases with age2, a significant proportion of patients with CVD are older 
with multiple co-morbidities. This affects disease progression and clinical outcomes, and can 
influence clinical decision-making3-5. Cardiovascular co-morbidities such as hypertension, 
diabetes, atrial fibrillation, heart failure and stroke have an independent association with 
increased mortality in patients hospitalised with acute myocardial infarction with increasing 
numbers of these co-morbidities particularly associated with poor outcomes6.  
 While previous studies have mainly focused on cardiovascular co-morbid conditions, 
patients with CVD often have a broad spectrum of non-cardiovascular comorbidities. It 
remains unclear, however, how clustering of multiple cardiovascular and or non-
cardiovascular chronic conditions influences clinical outcomes. Therefore, there is a need to 
understand the impact of co-morbid burden, rather than focusing on individual co-morbid 
conditions on clinical outcomes in patients with prevalent CVD2.  
 The Charlson co-morbidity index (CCI) is a recognized measure of co-morbid 
burden7and quantifies the prognostic impact of 22 co-morbid conditions based on their 
number and individual prognostic impact by means of a score8. It is a useful tool for 
estimating prognosis in patients with multiple co-existing illnesses. Table 1 represent the 
variables  Although various studies have evaluated the prognostic value of CCI in predicting 
outcomes in different cohorts of patients with CVD, there is no systematic review of the 
literature that evaluates the prognostic value of CCI on mortality across a range of 
cardiovascular diseases. In this systematic review, we sought to investigate the prevalence, 
and prognostic impact, of co-morbidity defined by the CCI score in patients with three major 
cardiovascular diseases; coronary heart disease, heart failure and cerebrovascular accident 
(CVA). 
Methods 
Study inclusion criteria 
 We included primary studies that evaluated the prognostic impact of co-morbid 
burden defined by Charlson co-morbidity index (CCI) in patients with coronary heart disease 
(CHD), acute or chronic heart failure and CVA.  Studies were considered for inclusion and 
detailed review if their abstract potentially met all three of the following criteria: 
1. Primary studies evaluating the impact of co-morbidity defined by CCI on adverse 
outcomes in patients with cardiovascular disease. 
2. Cardiovascular disease was defined by CHD (comprising of patients undergoing 
percutaneous coronary intervention or stable angina or acute coronary syndrome), or 
acute or chronic heart failure, or cerebrovascular disease. 
3. Adverse outcomes included: mortality, major adverse cardiac events (MACE) at any 
length of follow up. 
 We excluded studies that did not have results on outcomes defined by CCI score, but 
there was no restriction on the basis of language of study. We also excluded expert opinion 
and editorial reviews.  We included conference abstracts to minimize publication bias. 
Search strategy 
We searched MEDLINE and EMBASE on July 2015 using the broad search terms: 
("Charlson co-morbidity index " or "Charlson index" or "Charlson co-morbidity score" or 
"Charlson score”)and ("acute myocardial infarction" or "acute coronary syndrome" or 
"coronary heart disease" or "coronary artery disease" or "stroke" or "cerebrovascular disease 
"or "cerebrovascular accident" or "heart failure" or "cardiac failure") and ("mortality" or 
"death" or "major adverse cardiovascular event" or "major adverse cardiac event" or 
"cardiovascular disease"). The search results were reviewed by two independent investigators 
(MR, CSK) for studies that met the inclusion criteria and relevant reviews were identified.  
Additional studies were retrieved by checking the bibliographies of included studies and 
relevant reviews. 
Data extraction 
 Data were extracted from each study into preformatted tables generated in Microsoft 
Word. Data collected included year, country, number of participants, mean age of 
participants, percentage of male participants, participant inclusion criteria, follow up 
assessment, lost to follow up and results of association between CCI and outcomes.  With 
regards to quality assessment, we documented the design of the study, reliable method of 
ascertainment of outcomes, >10% loss to follow up and if there was any adjustment for 
potential confounders. 
Data analysis 
 Meta-analysis for estimated pooled risk ratios (RR) was performed by the inverse 
variance method using a random effects model on the software RevMan 5.3 (Nordic 
Cochrane Centre, København, Denmark). To reduce the risk of confounding associated with 
crude estimates, where available, we chose to pool the results from the most adjusted model, 
whereby results were expressed as pooled relative risk ratios (RR) with accompanying 95% 
confidence intervals (CI).  Statistical heterogeneity was assessed using the I2 statistic, with 
values of 30-60% representing a moderate level of heterogeneity9. For I2>50%, we performed 
sensitivity analysis by systematic exclusion of studies and evaluated the effect on I2 estimates (Supplementary Table 1). The primary analysis evaluated adverse outcomes with 
incremental increase in CCI and secondary analysis was performed by considering higher 
group of CCI score versus lower group of CCI score. In the final analysis, we excluded 
studies by the same research group over the same time period where there was the potential 
that the same participants were studied more than once.  Where there were similar study 
participants, we chose the study with the largest sample size or highest adverse outcome 
event rate.  We evaluated publication bias through Funnel plots and Egger’s test where there 
were >10 studies in the analysis and no evidence of statistical heterogeneity as the power to 
detect publication bias was low for meta-analyses of 10 or fewer studies10. 
 
Results 
Description of included studies 
 A total of 35 11-45 studies met the inclusion criteria. The process of study selection is 
shown in Figure 1.  The details of the studies design and participants are described in Table 
21.  The included studies comprised 14 retrospective cohort studies11, 12, 15, 17, 18, 21-23, 27, 30, 32, 
33, 37, 4317 prospective cohort studies13, 14, 16, 19, 20, 28, 29, 31, 34-36, 38-42 1 post-hoc analysis of 
registry25, and 1 post-hoc analyses of RCT45 whilst 2 abstract studies24, 26 were not clear in 
reporting the design. There were a total of 1,538,793 participants in 35 studies. 24 studies 
reported a mean age of 71 years and 62% male. The study size varied from 93 participants31 
to 798,328 participants21. The follow up time ranged from 30 days to 5 years. 
 17 studies12-16, 19, 20, 22, 23, 25, 28, 29, 31, 34-36, 38, 42 reported individual CCI scores and 530,457 out 
of 1,538793 (35%) patients had no co-morbidities (CCI=0). The prevalence of each co-
morbid condition in each of the cardiovascular conditions / events studied is presented in 
Figure 2. Diabetes and a history of previous myocardial infarction were the two most 
common conditions present in patients with coronary heart disease. Approximately 10% of 
the patients with heart failure had previous history of myocardial infarction (only reported in 
6 studies out of the total 13) and 12% had a history of chronic obstructive airways disease 
(COPD). Similarly, diabetes was the most prevalent co-morbidity in the patients with CVA 
cohort. Hematological malignancies such lymphoma leukemia and AIDS were the least 
frequent co-morbid conditions across all the cohorts studied. 
 
Quality assessment of included studies 
 The quality of studies included is described in Table 32. There was no loss to follow 
up for 13 of the included studies. 22 studies had less than 10% loss to follow up. The largest 
absolute loss to follow up was reported by Radovanovic et al.as they excluded 1091 patients 
from final results due to unavailability of CCI data31.  Just over half of the studies12-14, 18, 19, 21, 
24, 25, 29, 35-37, 39-42, 44, 45 (18 out of 35) reported estimates of associations adjusted for potential 
confounders. 
 
Results of included studies 
 The characteristics of patients included in the studies and association of CCI score on 
outcomes in described in Table 43.  
 
Acute coronary syndrome (ACS) 
A total of 11 studies11, 17, 18, 21, 22, 28, 32, 33, 36, 37evaluated the impact of co-morbidity in 
1,154,408 patients admitted with ACS. However, only 5 studies 11, 21, 28, 31, 37 reported on 
patients with no co-morbidity (37% of patients had CCI=0). 5 studies17, 18, 31, 32, 36 were 
statistically pooled for the association between an incremental increase in CCI and mortality 
(Figure3A). Among patients with ACS, the risk of death was significantly greater with 
incremental increase in CCI score RR 1.33 (95%CI 1.15-1.54). 3 studies, I2=96% 11, 21, 31 
compared patients with no co-morbidity (CCI score=0) versus patients with any co-morbidity 
(CCI score>0) showing that the presence of co-morbidity (CCI score>0) resulted in almost 
twice the risk of death RR 1.93 (95% CI 1.67-2.24). Radovanovic et al.31 and Huang et al.21 
also analysed the impact of CCI score 0-1 versus >1 showing a higher risk of death in 
patients with CCI score >1 (RR 2.26 95%CI 1.23-4.16, I2=98%). 3 studies21, 31, 37 
demonstrated a more than two-fold rise in mortality in patients with CCI score >2 comparing 
to a score of 0-2. Only 1 study16 compared CCI score 0-3 vs >3 which reported higher 
mortality (RR 5.89 95%CI 5.56-6.24) in patients with more co-morbidities (CCI score >3). 
In an ACS registry (AMIS registry), Jeger et al.22 reported an increase risk of MACE 
(a composite end point of re-infarction, CVA, and or death) over a one-year follow up period 
in patients with CCI score ≥2. In another study, Nunez et al.28 demonstrated that a higher CCI 
score was an independent predictor of mortality or acute myocardial infarction at 30 days and 
1 year. 
 
Stable coronary heart disease 
2 studies14, 35 studied the relationship between incremental rise in CCI score and 
mortality in patients with stable coronary heart disease (Figure 3B) suggesting that 
incremental increases in CCI score were associated with worse outcomes (RR 1.38 95%CI 
1.29-1.48, I2=0%). Sachdev et al.35 also reported that patients with a CCI score of 0 have 
better long-term survival (RR 1.88 95%CI 1.48-2.38). They also reported that almost half of 
the patients (49%) included in the cohort were disease free and had no comorbidities 
(CCI=0). 
Patients undergoing PCI 
Lastly, 5 studies16, 20, 25, 38, 44reported impact of CCI on long term survival in patients 
undergoing PCI, out of which 4 indicated that mortality increases with each point rise in CCI 
score RR 1.21 95%CI 1.12-1.31, I2=71% (Figure 3C). Only Mamas et al.25 reported about 
patients with no comorbidities in their study.  
Heart failure 
 A total of 13 studies reported the influence of co-morbidity in 63,609 patients with an 
underlying diagnosis of heart failure. An increased risk of mortality (RR 1.21 95%CI 1.13-
1.29, I2=48%) was observed per point increase in CCI score amongst 4 studies13, 15, 26, 41. Jong 
et al.23 and Rodriguez-Pascual et al.34 compared patients with CCI score 0-1 versus >1, and 
demonstrated that a CCI score >1 was associated with an increased risk of death (RR 1.60 
95%CI 1.52-1.70, I2=0%). Similar trends were observed in studies that compared a CCI score 
>2 with a CCI score of 0-2. For instance, 3 studies23, 29, 30 reported an increased risk of death 
(RR 1.76 95%CI 1.65-1.87, I2=0%) in patients with CCI score of greater than 2. Patients with 
high burden of comorbidities (CCI score >4) were analyzed in 3 studies29, 34, 42 which showed 
almost three fold increase in relative risk of mortality (RR 2.93 95%CI 1.99-4.31, I2=15%). 2 
studies27, 45 reported increased risk of death with higher co-morbid burden with hazard ratio 
>1 but it was unclear how they are related to CCI score. Both studies were only available in 
abstract form and, therefore, not included in the final meta-analysis. More interestingly 
Subramanian et al.39 assessed the impact of incremental increase in CCI per 3 points in heart 
failure patients over 5 years reporting increase risk of death (HR 1.39 95%CI 1.16-1.67) with 
growing burden of comorbidities. 
 
Cerebrovascular accident (CVA):  
A total of 4 studies analyzed the impact of CCI score on survival in patients with an acute 
CVA. Khawaja et al24 reported a no significant increase risk of death with incremental 
increase in CCI score (RR 1.05 95%CI 0.91-1.21). However, higher CCI score >2 had 
significant impact on mortality (RR 3.80 95%CI 1.20-12.01, I2=84%) when compared with 
low CCI score 0-2. 
Discussion 
 In this study we evaluated the prevalence and prognostic impact of co-morbidities as 
defined by CCI in patients with CHD heart failure and CVA. We observed a significant 
burden of co-morbidity in patients with CV disease –two thirds of patients included in the 
analysis had at least one chronic condition. The most common CV comorbid conditions 
identified in patients with CHD were diabetes and history of prior myocardial infarction, 
whereas COPD and kidney disease were the most frequent non-cardiovascular conditions. To 
our knowledge, this is the first study to systematically show the impact of co-morbid burden 
as defined by CCI on survival in patients with coronary heart disease, heart failure and CVA. 
We found that the presence of co-morbidities had a significant incremental prognostic impact 
in patients with a broad range of CV disease.  
 CHD is the commonest cardiovascular disease affecting 1 in 7 people in USA46 and 
UK every year. Patients with CHD are likely to have higher number of coexisting illnesses 
either in the form of prevalent cardiovascular risk factors such as diabetes, hypertension or 
direct manifestations of coronary heart disease such as prior myocardial infarction or heart 
failure. For instance, in one study, diabetes, hypertension and heart failure were found to be 
most frequently encountered coexisting illnesses in patients admitted with ACS and 68% of 
the participants had at least three comorbidities47. The rising burden of co-morbidity has been 
reported to have inverse relationship with survival outcomes in patients with CHD. In our 
analysis, incremental rise in CCI was associated with significant increase in mortality and the 
risk of death was almost doubled with presence of any co-morbidity compared to the patients 
with no co-morbidity (Figure 3A). This has important clinical implications in this cohort of 
patients as the prevalent cardiovascular risk factors such as hyperlipidemia, smoking and 
other related cardiovascular comorbidities such as hypertension, diabetes in patients with 
coronary heart disease are usually treated aggressively but there is growing evidence that non 
cardiovascular disease burden may also contribute to increase risk of mortality 25, 31. We 
report that CCI is not only a simple way of quantifying comorbid burden but also provides 
prognostic value in ascertaining outcomes. Clinicians often use various risk assessment tools 
such GRACE, TIMI scores in determining the type of intervention, treatment plan and 
allocation of resources in managing patients with ACS. Although these models have been 
validated in the predicting the adverse events 48, 49 the clinical data incorporated in these 
models do not take into account the co-morbid burden of the patients. Previous studies have 
suggested that the performance of such risk models improves when co-morbidity scores such 
as CCI are added to the risk scores17 and may help in better allocations of resources and 
developing robust treatment pathways for patients with multiple comorbidities. Our study 
highlights the importance of taking into consideration of the overall co-morbid burden in 
such patients whilst making the therapeutic decisions. Furthermore, our study also demonstrates that comorbidity burden has prognostic value.  
 The prevalence of heart failure is increasing due to the aging population and better 
survival from acute cardiac events50. Our findings reinforce the hypothesis that heart failure 
patients with multiple comorbidities have worse outcomes15. Similarly, increasing comorbid 
burden is associated with a worse prognosis in patients after an acute cerebrovascular event. 
We observed that the risk of death was almost four fold greater in patients with two or more 
co-existing illnesses (Figure 5). 
 The mechanism by which the co-existing co-morbid burden influences outcomes in 
patients with cardiovascular disease is complex and multifactorial. Older and frailer patients 
with high burden of comorbidities are more likely to be treated conservatively following a 
cardiovascular event 51, 52. For instance, a large national ACS registry reported an incremental 
reduction in provision of evidence-based treatments such as aspirin, statins, ACE inhibitors 
and reperfusion therapy to the older multi-morbid patients 53. In another recent analysis of 
18,814 patients, Patel et al identified that patients with higher comorbid burden as defined by 
CCI were less likely to receive coronary artery angiography and or/ revascularization 
following presentation with STEMI54. Similarly thrombolysis therapy in acute ischemic 
stroke is usually reserved for younger patients with no significant burden of comorbidities 
due to fear of less favorable outcomes such as bleeding complications in elderly patients with 
multiple comorbidities55. In the management of patients with chronic heart failure, the 
associated burden of comorbidities may limit the use of medications such as ACE inhibitors 
or spironolactone particularly in patients with severe chronic kidney disease56 and beta-
blockers in patients with coexisting severe COPD. Furthermore, patients with multiple 
chronic conditions are less likely to receive invasive therapies such as implantable 
cardioverter-defibrillators (ICD) or cardiac resynchronization therapy57. There is also 
growing evidence that increasing burden of comorbidities in patients with heart failure is 
associated with repeated hospitalization and poor outcomes58, 59. 
 Provision of aggressive treatment strategies in patients with multi-morbidity can lead 
to higher incidence of complications and adverse outcomes. For example, Patients with 
leukemia are at higher risk of stent thrombosis60 and those with liver dysfunction are at 
increase risk of bleeding complications post PCI and cardiac mortality61. Similarly, the 
presence of diabetes and hematological disorders has been shown to increase the risk of 
hemorrhagic transformation in patients with ischemic stroke62, 63. Consequently, the presence 
of co-existing diseases may drive poor outcomes in patients with CHD due to reduced scope 
of treatment options and increased risk of complications. Hence, clinicians may be reserved 
in deciding treatment strategies whilst managing patients with multi-morbidity due to the 
challenge of finding a balance between risk and benefit of an intervention64, 65.  
 Other factors that may be responsible for deleterious effect of comorbidities on 
survival outcomes are presence of coexisting illness sharing the same pathophysiology and 
adverse drug reactions (ADRs) due to polypharmacy. For example, presence of anaemia 
results in low cardiac output state and has been reported to have synergetic impact on the 
mortality in patients with chronic heart failure66.  
 Our findings have important implications in management of patients with CHD, heart 
failure and cerebrovascular disease.  Treatment options such as medical therapies, PCI, 
surgical revascularization, device therapies and thrombolysis are now readily available to 
wider spectrum of patients. Although international guidelines 67, 68 advocate a comprehensive 
assessment of patients taking into account their comorbid status, contemporary risk 
stratification tools such as GRACE, Cath PCI, Syntax are derived from datasets based on 
patient’s characteristics, procedural demographics and cardiovascular risk factors and do not 
take into account patients co-morbid burdens. Our analysis shows that CCI score has 
prognostic value in our cohort of patients and using CCI alongside these risk models can help 
physicians to ascertain outcomes and better resource allocation.  For instance the addition of 
CCI to the Mayo Clinic Risk Score for PCI increased net re-classification index by 34% and 
improved the c-statistic for the model significantly38. Erickson et al 17 also tested the risk 
prediction of GRACE model by adding CCI and observed a significant improvement in 
predicting outcomes in ACS patients. Another study reported improved discriminative 
performance of GRPI (GRACE risk prediction Index) score when added with CCI in 
predicting future cardiac related events post myocardial infarction17. Therefore, the 
assessment of co-morbid status and its impact on long term survival should be integrated into 
the counseling of the patients before deciding the choice of treatment in conjunction with 
traditional risk assessment. 
 Our study has several strengths and limitations. To our knowledge this is the first 
review on impact of co-morbidity defined by CCI on major cardiovascular disease such as 
CHD, heart failure and cerebrovascular disease. We were able to analyse the impact of per 
unit rise in CCI in our cohort of patients demonstrating that rise in CCI score has inverse 
relationship with survival. We were also able to evaluate the impact of CCI amongst 
individual cohorts of coronary heart disease namely stable angina, ACS and those undergoing 
PCI and found a uniform negative impact of rising CCI score across all cohorts. Additionally 
we also studied the prevalence of comorbidities in patients with cardiovascular disease and 
found that majority of patients in this cohort have significant burden of comorbidities.  
Our study was limited by the incomplete reporting of original studies and was reliant on the 
published data available. We were not able to evaluate the impact of individual components 
of CCI on mortality, as this was not consistently reported across all studies.  Furthermore, the 
studies included in our review were mainly observational, which have their own inherent 
limitations and may be subject to selection biases and unmeasured confounders. Another limitation is that we found significant heterogeneity in several analyses.  This may be because many of the studies are large with very narrow confidence intervals leading to statistical heterogeneity when there is little overlap in 95% confidence amongst the studies.  However, all the studies in general report estimates that are consistently significant and favour increased events with higher CCI score.  The statistical heterogeneity arises from differences in each study in terms of population evaluated and study methodology which leads to variation in estimates for the prognostic value of CCI.  
 
Conclusion:  
Our study shows that co-morbid burden defined by CCI is significant across a broad range of 
cardiovascular conditions and has significant impact on survival in patients with coronary 
heart disease, heart failure and CVA. Assessment of co-morbid burden using CCI provides a 
method of quantifying risk associated with comorbidities in patients with CV disease and 
should be incorporated into decision making processes when counseling patients regarding 
risk and benefits of treatment in conjunction with allocation of resources.  
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Figure 1: Flow diagram of study selection 
 
  
 
 
 
 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1162 results from search of MEDLINE and EMBASE using the following search terms on 13th July 2015 using the broad search terms: ("Charlson co-morbidity index " OR "Charlson index" OR "Charlson co-morbidity score" OR "Charlson score”) AND ("acute myocardial infarction" OR "acute coronary syndrome" OR "coronary heart disease" OR "coronary artery disease" OR "stroke" OR "cerebrovascular disease " OR "cerebrovascular accident" OR "heart failure" OR "cardiac failure") AND ("mortality" OR "death" OR "major adverse cardiovascular event" OR "major adverse cardiac     
247 potentially relevant articles. 
915 studies excluded because they did not meet inclusion criteria based on reviewing the title/abstract.  212 studies excluded because they did not meet inclusion criteria after reviewing full text where available. 35 studies included in the review. 
Figure 2: Charlson co-morbidity individual component distribution  2A): 
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Figure 3: ACS patients, stable angina/stable coronary heart disease patients,  and 
patients undergoing PCI and mortality according to CCI 
 
A) Acute coronary syndrome 
 
 
B) Stable angina/stable coronary heart disease 
 
 
 
C) Patients undergoing PCI 
 
Figure 4: Heart failure patients and mortality according to CCI 
  
 
 
 
 
Figure 5: CVA patients and mortality according to CCI 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Charlson co-morbidity index 
 
Variable Points 
Myocardial infarction 1 
Congestive heart failure 1 
Peripheral vascular disease 1 
Cerebrovascular disease 1 
Dementia 1 
Chronic obstructive pulmonary disease 1 
Connective tissue disease 1 
Peptic ulcer disease 1 
Diabetes mellitus 1 if uncomplicated 
2 if end-organ damage 
Moderate to severe chronic kidney disease 2 
Hemiplegia 2 
Leukemia 2 
Malignant lymphoma 2 
Solid tumour 2 
6 if metastatic 
Liver disease 1 if mild 
3 if moderate to severe 
AIDS 6 
 
  
Table 2: Study design and characteristics of participants 
Study ID Study design; Year; Country No. of Participants Participants 
with CCI=0 
(%) 
Mean age 
 
% Male 
 
Description of participants 
Bottle 201311 Retrospective cohort study; 
2006 to 2009; UK. 
288,550.  15,177. 
(5%) 
42% of 
admissions 
>75 years 
of age. 
61%. Participants were emergency admissions for ACS in 
England. 
Bar 201112 Retrospective cohort study; 
2001 to 2004; USA. 
243. 88.(36%) NA. NA. Patients with non-traumatic intra cerebral hemorrhage 
presented to hospital emergency department. 
Chin 199813 Prospective cohort study; 1993 
to 1994; USA. 
257.  48.(18%) Full cohort 
41% >70 
years of 
age.  
Full cohort 
47%. 
Participants were admitted with congestive heart failure 
to the Brigham and Women’s Hospital. 
Chirinos 
200614 
Prospective cohort study; 1998 
to 2000; USA. 
305. 70.(22%) 64 years. 100%. Male Veterans undergoing coronary angiography at 
Miami Veterans Administration Medical Centre. 
Clarke 201115 Retrospective cohort study; 
1998 to 2004; Canada. 
824. NA. 64 years. 69%. Consecutive patients followed at a tertiary care 
specialty ambulatory heart failure clinic. 
Eberli 201316 Prospective registries; NA; 
International. 
5,559. 2041.(36%) NA. NA. Participants from e-Biomatrix PMR and PMS registries 
evaluating the efficacy and safety of biolimus-A9-
eluting stent. 
Erickson 
201417 
Retrospective cohort study; 
1999 to 2007; USA. 
1,202. NA. 64 years. 65%. Participants from ACS registry from a large university 
hospital. 
Fabbian 201318 Retrospective cohort study; 
1999 to 2009; Italy. 
88,014. NA. 71 years. 48%. Participants from database of Emilia-Romagna region 
Italy who presented with first event of myocardial 
infarction.  
Goldstein 
200419 
Prospective cohort study; 
1995-1997; USA. 
960. 212.(22%) 68 years. NA. Participants admitted with ischemic stroke Department 
of Veterans Affairs (VA) Stroke Study. 
Hong 201120 Prospective cohort study; 2006 
to 2008; International. 
675. NA. 83 years. 58%. Octogenarian participants from Sirolimus-eluting 
coronary stent (e-Select) registry. 
Huang 201521 Retrospective; 2002 to 2011; 
Taiwan. 
798,328.  315,556.(39
%) 
45% ≥65 
years. 
57% 
 
Participants with disabilities from the National Health 
Insurance Research Database published by the Ministry 
of Health and Welfare in Taiwan. 
Jeger 201422 Retrospective; 2005 to 2012; 
Switzerland. 
1909. NA. 65 years. 78%. Participants from AMIS plus registry. 
Jong 200223 Retrospective; 1994 to 1997; 
Canada. 
38,702. 15,020.(38
%) 
85% ≥65 
years. 
49%. Participants from Canadian institute for health 
information database admitted with first diagnosis of 
heart failure. 
Khawaja 
201424 
NA; 2008 to 2013; USA. 383. 37.(9%) NA. NA. Patients with primary intra cerebral haemorrhage. 
Mamas 201525 Post hoc-analysis of 
prospective registry; 2008 to 
2013; International. 
3,067. 787.(25%) 64 years. 78%. Participants were in the Nobori 2 study who underwent 
Nobori biolimus-eluting stent implantation. 
Menendez-
Colino 201326 
NA; Spain. 652. NA. 85 years. NA. Patients admitted with heart failure in six Spanish 
hospitals. 
Munoz-Rivas 
200927 
Retrospective cohort study; 
2005 to 2007; Spain 
270. NA. 78 years. 42%. Patients with chronic heart failure diagnosis. 
Nunez 200428 Prospective Cohort study; 
2000 to 2003, Spain. 
1,035. 481.(46%) 70 years. 70%. Patients admitted with diagnosis of acute myocardial 
infarction. 
Oudejans 
201229 
Prospective cohort study; 2003 
to 2007; Netherlands. 
93. 0. 83 years. 37%. Patients with diagnosis of heart failure. 
Perez-Barquero 
201030 
Retrospective cohort study; 
2000 to 2001; Spain 
2127. NA. 77 years. 43%. Patients admitted with heart failure to various hospitals 
in Spain. 
Radovanovic 
201431 
Prospective cohort study; 2002 
to 2012; Switzerland. 
29,620. 15 
754.(51%) 
64 years. 73%. Participants from AMIS plus registry. 
Ramirez-
Marrero 201132 
Retrospective cohort study; 
2004 to 2005; Spain  
715. NA. 66 years. NA. Patients admitted with diagnosis of  NSTEACS. 
Ramirez-
Marrero 201333 
Retrospective cohort study; 
2008 to 2009; Spain 
146. NA. 78 years. 63%. Patients undergoing percutaneous coronary 
revascularization. 
Rodriguez-
Pascual 201234 
Prospective cohort study; 2006 
to 2009. 
581. 121.(20%) 86 years. 33%. Patients admitted to an acute geriatric unit with 
decompensated heart failure. 
Sachdev 200435 Prospective cohort study; 1985 
to 1989; USA. 
1,471. 810.(55%) 60 years. 72%. All patients undergoing initial coronary angiography for 
symptoms of chronic CAD and found to have 
significant disease (≥75% stenosis) in one or more 
coronary arteries. 
Sanchis 201136 Prospective cohort study; 2002 
to 2009; Spain. 
1,017. NA. 68 years. 66%. Patients admitted with diagnosis of NSTEACS. 
Schmidt 201237 Retrospective cohort study; 
1984 to 2009; Denmark. 
234,331. 164 
937.(70%) 
75 years. 62%. Patients from nationwide Danish cohort registry 
admitted with myocardial infarction. 
Singh 201138 Prospective cohort study; 2005 629. NA. 75 years 69% Patients undergoing PCI at the Mayo Clinic in 
to 2008; USA. Rochester, USA. 
Subramanian 
200739 
Prospective cohort study; 
unclear; USA. 
494. NA. 68 years. NA. Participants from Veterans Affairs outpatients with 
diagnoses of CHF. 
Teng 201440 Prospective cohort study; 2000 
to 2009; Australia. 
17,379. 105.(0.6%) 70 years. 58 %. Participants were Aboriginal and non-Aboriginal 
patient with first heart failure hospitalization. 
Testa 200941 Prospective cohort study; 1992 
to 2003; Italy. 
1,268. NA. 74 years. 43%. Participants from ‘Osservatorio Geriatrico Regione 
Campania’ with and without heart failure. 
Theuns 201142 Prospective; 1999 to 2008; 
International. 
463. NA. 62 years. 75%. Participants from two ICD registries from Rotterdam 
and Basel. 
Tuttolomondo 
200843 
Retrospective; 1988 to 1998; 
Italy. 
1,878. 0. 77 years. 49%. Participants from GIFA registry. 
Urban 201144 Prospective cohort study; 2006 
to 2008; International. 
15,147. NA. 62 years. 75%. Participants from Sirolimus-Eluting Coronary Stent 
implantation study (e-Select) registry. 
Van Wijk 
201345 
Post hoc analysis of RCT; 
Unclear; International. 
499. NA. NA. NA. Participants from heart failure study randomized to 
intensified NT-proBNP-guided versus symptom-guided 
therapy. 
NA=not available or not reported.  
Table 2: Quality of included studies 
Study ID Prospective study design Reliable ascertainment of outcomes Less than 10% loss to 
follow up 
Use of adjustments for potential confounders 
Bottle 201311 No, Retrospective. Yes, Death from death certificates from the Office 
for National Statistics. 
Unclear. None. 
Bar 201112 Yes, Prospective. Unclear, Outcome assessed using modified 
Rankin scale out to 12 months by unclear 
methods. 
Unclear Adjusted for presence of IVH, infratentorial 
ICH and use of early DNACPR orders. 
Chin 199813 Yes, Prospective. Yes, Death from chart review, survey of families 
and search of the National Death Index. 
Yes, 7 patients 
discharged quickly and 
unreachable, 5 too sick 
for interview. 
White ethnicity, age ≥70 years, prior 
congestive heart failure, chronic pulmonary 
disease, Charlson Co-morbidity Index score, 
third heart sound, serum sodium ≤135, EF 
<0.50, diabetes, respiratory rate >30/min, 
cardiomegaly on admission chest radiograph. 
Chirinos 200614 Yes, Prospective. Yes, Patients interview and review of hospital 
electronic records. 
Yes, 9 patients were 
lost to follow up. 
Multivariate analysis adjustments for age, 
left ventricular ejection fraction, congestive 
heart failure, and number of coronary artery 
territories involved with haemodynamically 
significant lesions. 
Clarke 201115 No, Retrospective. Yes, Electronic database, review of medical 
notes, clinic visits and review of death 
certificates. 
Yes, None. None. 
Eberli 201316 Yes, Prospective. Unclear, One year all cause and cardiac mortality 
by unclear method. 
Unclear. None 
Erickson 201417 No, Retrospective. Yes, Six months post discharge all cause 
mortality or secondary cardiovascular events or 
revascularization procedures. 
Yes, None. None 
Fabbian 201318 No, Retrospective. Yes, In-hospital mortality for myocardial 
infarction. 
Yes, None. Chronic kidney disease. 
Goldstein 
200419 
Yes, Prospective. Yes, Death at discharge and 1 year mortality. Yes, None. Initial stroke severity. 
Hong 201120 Yes, Prospective. Yes, Followed up at 30, 180, and 360 days by 
telephone communication, office visit, or by 
contacts with primary physicians or referring 
cardiologists for 1-year mortality, stent 
thrombosis.  
Yes, None. Unclear. 
Huang 201521 No, Retrospective. Yes, Data collected from National Health 
Insurance Research Database and the National 
Disability Registration Database of Taiwan. 
Yes, None. Adjusted (Model A);variables unclear. 
Jeger 201422 No, Retrospective. Yes, Data collected from AMIS plus registry. Yes, 161 lost to follow 
up. 
None. 
Jong 200223 No, Retrospective. Yes, 30 days and one-year mortality ascertained 
by linking the database with Ontario registered 
person database. 
Yes, None. None. 
Khawaja 201424 Unclear. Unclear, Primary outcomes of modified Rankin 
scale of 4-6, death and poor discharge disposition 
(any disposition other than home or inpatient 
rehabilitation) assessed by unclear methods. 
Unclear. Adjusted for baseline ICH score. 
Mamas 201525 Yes, Prospective. Yes, Data was collected into a Web-based data 
management system and an independent clinical 
events committee adjudicated all events. 
No, 326 lost to follow 
up at 5 years. 
Adjusted for baseline demographic and 
lesion characteristic variables with p<0.05. 
Menendez-
Colino 201326 
Unclear. Unclear, Mortality at 12 months. Unclear follow 
up methods. 
Yes, 25 patients. Unclear. 
Munoz-Rivas 
200927 
No, Retrospective. Unclear. Unclear. Unclear. 
Nunez 200428 Yes, Prospective. Yes, 30 days and 1-year mortality or reinfarction 
at outpatient follow up and telephonic contact. 
Yes, None. None. 
Oudejans 
201229 
Yes, Prospective. Yes, All cause mortality within 3 years. Follow 
up information obtained from hospital 
information system or from patient’s general 
practitioners. 
Yes, 1 patient was lost 
to follow up. 
Age, gender, LVEF, and NT-proBNP. 
Perez-Barquero 
201030 
No, Retrospective. Unclear, In hospital mortality by unclear follow 
up methods. 
Unclear. Unclear. 
Radovanovic 
201431 
Yes, Prospective. Yes, Data collected from AMIS plus registry.  No, 1091 patients CCI 
data was not available. 
None. 
Ramirez-
Marrero 201132 
No, Retrospective. Unclear. Yes, None. None. 
Ramirez-
Marrero 201333 
No, Retrospective. Yes, Cardiovascular mortality during follow-up. Yes, None. None. 
Rodriguez-
Pascual 201234 
Yes, Prospective. Unclear, Mortality. Unclear. None. 
Sachdev 200435 Yes, Prospective. Yes, Patients were followed up at six months, one 
year, and then annually by a mailed questionnaire, 
with telephone backup, as well as a National 
Death Index search for non-responders through 
December 2000. 
Yes, None. Adjusted for age, unclear if other variables 
were adjusted. 
Sanchis 201136 Yes, Prospective. Yes, Data collected from admission records and 
follow up. 
Yes, 4 patients did not 
complete follow up. 
Adjusted for variables with p<0.05 but 
variables unclear. 
Schmidt 201237 No, Retrospective.  Yes, Standardized incidence rate of myocardial 
infarction and 30 day and 31–365 day mortality 
by sex. 
Unclear. Age and sex. 
Singh 201138 Yes, Prospective. Yes, All-cause mortality during follow-up. The 
second main outcome was MI defined as presence 
of 2 of 3 following criteria: prolonged (>20 
minutes) ischemic chest pain and elevation of 
cardiac biomarkers (creatinine kinase-MB or 
relative index) more than 2 times upper limit of 
normal, or electrocardiographic changes (ST/T-
wave changes or new Q waves).  
Yes, 2% participants 
lost to follow up. 
None. 
Subramanian 
200739 
Yes, Prospective. Yes, 5-year mortality during follow up data 
obtained from Veterans Integrated Health 
Systems Technology Architecture databases. 
Yes, 35 patients were 
excluded for missing 
values. 
Adjusted; variables unclear. 
Teng 201440 Yes, Prospective. Yes, Data was collected from the Hospital 
Morbidity Data Collection which is linked to the 
Mortality register. 
Unclear. Adjusted; variables unclear. 
Testa 200941 Yes, Prospective. Yes, All subjects were contacted at home or in 
their institution and examined by physicians 
trained to administer a questionnaire. 
Yes, 35 patients were 
unreachable and 9 did 
not have social support. 
Age, sex, heart rate, systolic blood pressure, 
Diastolic blood pressure, Social support, 
Drugs number, MMSE, BADL, NYHA, 
CAD, COPD, neurological disease, CHF, 
and CCI. 
Theuns 201142 Yes, Prospective. Yes, The data collected from two prospective ICD 
registries from Rotterdam and Basel. Patient 
followed up at out-patient clinics. 
Yes, None. Adjusted for age. 
Tuttolomondo 
200843 
Yes, Prospective. Yes, Demographic data and follow up was 
collected from GIFA registry. 
Yes, None. None 
Urban 201144 Yes, Prospective. Yes, The data collected from the e-Select registry 
where patients were followed up at 30, 180 and 
360 days by telephone communication or office 
visit by contacts with primary physicians or 
referring cardiologist. 
Unclear. Adjusted for variables with entry p-value of 
0.10 and stay criterion of 0.15.  Unclear 
exact variables. 
Van Wijk 
201345 
Yes, Prospective. Yes, Clinically followed up for 18 months with 
recording of hospitalization, mortality and 
adverse events up to 5 years. 
Unclear. Adjusted; variables unclear. 
 
Table 4: Follow up and results of the association between Charlson Co-morbidity Index and outcome 
Study ID Type of 
population 
(CAD, HF, 
CVA) 
Definition of CCI Outcome and duration of 
follow up 
Results demonstrating association between CCI and outcome 
 
Bottle 201312 ACS (CAD) Charlson score 0 vs >0. 30-day mortality. 30 day mortality: CCI -0: 8,370/151,577 (5.5%), CCI >0: 20,999/177,792 
(11.8%) 
Bar 201111 Stroke (CVA) Incremental rise in CCI 
from 0 to >3. 
12 month functional 
outcome according to 
modified Rankin Scale. 
CCI-1: OR 1.78 (0.86- 3.70), CCI-2: OR 2.34 (0.98-5.61), CCI-3: OR 
3.48 (1.64-7.37). 
Chin 199813 HF Incremental increase in 
CCI. 
Time to mortality. Mortality per CCI point to max of 4 points: HR 1.3 (1.1-1.4). 
 
Chirinos 200614 Stable CAD  Incremental increase in 
modified CCI. 
All-cause mortality during 
58 month follow up. 
Odds of mortality with incremental increase in modified CCI score: OR 
1.32 (1.17-1.48). 
Clarke 201115 Heart failure 
(HF) 
Incremental increase in 
CCI. 
Time to mortality with 
follow-up of mean of 4.4 
years. 
Overall mortality by per unit increase in CCI: HR 1.26 (1.19-1.35). 
Eberli 201316 PCI (CAD) Mortality by different CCI 
score. 
1 year mortality and cardiac 
mortality. 
Overall one year mortality: CCI-0: 18/2,041 (0.9%), CCI-1: 28/2,162 
(1.3%), CCI-2: 18/776 (2.3%), CCI≥3: 25/578 (4.3%).  
Cardiac mortality: CCI-0: 14/2,041 (0.7%), CCI-1: 13/2,162 (0.6%), 
CCI-2: 9/776 (1.2%), CC I≥3: 14/578 (2.4%). 
Erickson 201417 ACS (CAD) Incremental increase in 
CCI. 
Inpatient and 6 months 
mortality and post discharge 
cardiac event or procedure. 
Inpatient death with CCI: OR 1.28 (1.14-1.43). 6 month death with CCI: 
OR 1.55 (1.41-1.72). Post discharge cardiac event or procedure CCI: 1.21 
(1.12-1.31). 
Fabbian 201318 ACS (CAD) Incremental increase in 
CCI. 
In-hospital mortality from 
MI. 
In-hospital mortality for MI with CCI without renal dysfunction:  OR 
1.101 (1.069-1.134). 
Goldstein 
200419 
Stroke (CVA) Low CCI 0-1 versus high 
CCI ≥2. 
1-year mortality. 1 year mortality with low CCI score 0-1:  88/551 (16%), high CCI score 
≥2: 106/429 (26%). 
Hong 201120 PCI(CAD) Incremental rise in CCI on 
outcomes. 
Time to mortality or stent 
thrombosis with follow-up 
up to 1-year. 
Every 1-point increment in CCI on death: HR 1.3 (1.1-1.5). 
Every 1-point increment on stent thrombosis: HR 1.5 (1.3-1.8). 
 
Huang 201521 ACS (CAD) Risk for each CCI score. Time to acute myocardial 
infarction. 
Adjusted model A (unclear variables): CCI score 1: HR 2.25(2.12-2.39), 
CCI score 2: HR 3.07(2.89-3.26), CCI score 3: HR 3.71(3.48-3.95), CCI 
score ≥4: HR 5.89 (5.56-6.25). 
 
Jeger 201422 ACS (CAD) Charlson score ≥2 1-year MACE. 1 year MACE with CCI score ≥2: OR 1.42(1.05–1.92). 
Jong 200223 
 
Heart Failure 
(HF) 
CCI score and mortality 
rate. 
30 days and 1-year 
mortality. 
CCI-0: 30 days mortality 1,397/15,020 (9.3%); one-year mortality 
4,025/15,020 (26.8%). 
 CCI-1: 30 days mortality 1,348/12,602 (10.7%); one-year mortality 
3,907/12,602 (31.0%).  
CCI-2: 30 days mortality 895/6485 (13.8%); one-year mortality 
2,555/6485 (39.4%).  
CCI-3: 30 days mortality 864/4,595 (18.8%); one-year mortality 
2325/4,595 (50.6%).  
Khawaja 201424 Stroke (CVA). Incremental increase in 
CCI score. 
Death at unclear follow up. Death and CCI score: OR 1.05 (0.91-1.21). 
Mamas 201525 PCI (CAD) Incremental increase in 
CCI score. 
30 day, 1-year and 5 year 
cardiac death and MACE. 
30-day: cardiac death OR 1.47 (1.20-1.80), MACE OR 1.27 (1.11-1.44). 
1-year: cardiac death OR 1.46 (1.30-1.65), MACE OR 1.32 (1.23-1.42). 
5-year: cardiac death OR 1.38 (1.24-1.53), MACE OR 1.29 (1.22-1.36).   
Menendez-
Colino 201326 
Heart Failure 
(HF). 
CCI score and mortality. Time to mortality with 
follow-up maximum of 12 
months. 
CCI score: HR 1.13 (1.04-1.24). 
Munoz-Rivas 
200927 
Heart Failure 
(HF) 
Incremental increase in 
CCI. 
Survival. Survival with incremental CCI: HR 1.46 (1.21-5.07). 
Nunez 200428 ACS (CAD) CCI score and risk 
compared to CCI 0. 
Time to death or reinfarction 
to a maximum of 30 days 
and 1-year. 
Risk of death or reinfarction at 30 days: CCI-1: HR 1.00, CCI-2: HR 1.69 
(1.10-2.59), CCI-3: HR 1.78 (1.08- 2.92), CCI-4: HR 1.57 (0.87-2.83). 
Risk of death or reinfarction at 1 year: CCI-1: HR 1.00, CCI-2: HR 1.62 
(1.18- 2.23), CCI-3: HR 2.00 (1.39-2.89), CCI-4: HR 2.24 (1.50-3.36). 
Oudejans 
201229 
Heart Failure 
(HF) 
CCI score 0-2 vs 3-4 or ≥4. Time to mortality to a 
maximum of 3 years. 
3 year mortality: CCI 0-2: HR 1.00. CCI 3-4: HR 1.5 (0.7-2.9), CCI >4: 
HR 4.0 (1.9-8.8).  
Perez-Barquero 
201030 
Heart Failure 
(HF) 
CCI score 1-2 vs ≥3 In hospital mortality. In hospital mortality: CCI 1-2: 76/1,528, CCI ≥3: 48/599. 
Radovanovic 
201431 
ACS (CAD) Incremental rise in CCI 
and risk compared to 
CCI=0. 
In hospital mortality and 1 
year mortality assessed 
using data from AMIS plus 
registry. 
In hospital mortality compared to CCI=0: CCI=1 OR 1.36 (1.16-1.60), 
CCI=2 OR 1.65 (1.38-1.97), CCI≥3 OR 2.20 (1.86-2.57). 
1-year mortality per CCI point: Age adjusted mortality OR 1.44 (1.36-
1.53). 
Ramirez-
Marrero 201132 
ACS (CAD) Higher CCI treated as 
incremental. 
In hospital mortality and 
median follow up of 24 
In hospital mortality: OR 1.6 (1.4-1.8), long-term mortality: OR 1.3 (1.2-
1.5), readmission for HF: OR 1.2 (1.04-1.3), MACE during follow-up: 
months. OR 1.1 (1-1.2). 
Ramirez-
Marrero 201333 
ACS (CAD) Highest CCI score.  Cardiovascular mortality 
during follow up of 36 
months. 
CCI and long term mortality: OR 1.72 (1.09-2.71). 
Rodriguez-
Pascual 201234 
Heart failure 
(HF) 
CCI score. Mortality. Mortality by CCI score: 0-1 5/121, 2-4 17/227, ≥5 26/194.  
Sachdev 200435 Stable CAD CCI scores of 0,1 and ≥2 Time to mortality during 
follow up period of almost 
11 years. 
CCI 0: 95/810 (11.7%), CCI 1: 58/378 (15.3%), CCI ≥2: 88/283 (31.1%). 
Incremental increase in modified CCI HR 1.41 (1.30-1.53). 
Sanchis 201136 ACS (CAD) Incremental increase in 
CCI per point. 
Time to mortality to a 
maximum of 1 year. 
Per point increase in CCI: aHR1.3 (1.2-1.4). 
Schmidt 201237 ACS (CAD). CCI=0 (normal) versus ≥3 
(very severe). 
30 days and 31-365 days 
mortality. 
30 days mortality: RR 1.96 (1.83-2.11). 31-365 days mortality: RR 3.89 
(3.58-4.24). 
Singh 201138 PCI (CAD). Incremental increase in 
CCI per point. 
Time to mortality or 
myocardial infarction during 
median follow up of 35 
months. 
Death during follow up: HR 1.12 (1.06-1.18). Death /MI during follow 
up: HR 1.05 (1.01-1.10). 
Subramanian 
200739 
Heart Failure 
(HF). 
Incremental increase in 3 
points of CCI. 
Time to mortality at follow 
up of up to 5 years. 
5 year all-cause mortality: HR 1.39 (1.16-1.67). 
Teng 201440 Heart Failure 
(HF). 
CCI unclear if incremental 
or cutoff. 
 
1 year mortality. 1 year mortality with CCI: <55 years HR 1.38 (1.26-1.51), ≥55 years HR 
1.20 (1.18-1.22).  
Testa 200941 Heart Failure 
(HF). 
Incremental increase in 
CCI score. 
Time to mortality to a 
maximum follow-up 12 
years. 
12 year mortality with CCI: HR 1.15 (1.01-1.31). 
Theuns 201142 Heart Failure 
(HF). 
CCI score>5. Time to all-cause mortality 
during a median follow up 
of 30.5 months. 
All-cause mortality: HR 3.49 (2.06-6.60). 
Tuttolomondo 
200843 
Stroke (CVA). CCI <2 versus CCI >2 In-hospital mortality. In-hospital mortality: OR 35.7 (4.8-265.2). 
Urban 201144 PCI (CAD) Incremental increase in 
CCI per point. 
Time to death, stent 
thrombosis and major 
bleeding at maximum of 1 
year. 
1 year death: HR 1.2 (1.1-1.2). 1 year stent thrombosis:  HR 1.2 (1.1-1.4). 
1 year major bleeding: HR 1.1 (1.0-1.2). 
Van Wijk 
201345 
Heart Failure 
(HF) 
Incremental increase in 
CCI score. 
Hospital free survivals 
during follow up period. 
CCI score: HR 2.47 (1.27-4.83). 
 
Supplementary Table 1: Sensitivity analysis Overall analysis No. of studies Results and heterogeneity Source of heterogeneity in sensitivity analysis No. of studies Results and heterogeneity in sensitivity analysis Possible reasons for heterogeneity (See table 2 & 3 for full details). Incremental increase in CCI and ACS cohort 5 1.33 (1.15-1.54), I2=96% Exclusion of Fabbian 2013 reduced I2 to 73%.  Further exclusion of Ramirez-Marrero 2011 reduced I2 to 66%. 
4 
 3 1.39 (1.28-1.52), I2=73% 1.35 (1.25-1.46), I2=66% 
Erickson 2014 was a retrospective study, with shorter follow up (6-months) and no adjustments of potential confounders. Radovanovic was a large prospective study with significant number of patients (1091) lost to follow up and no adjustment of potential confounders. Sanchis 2011 is a small prospective study which adjusted for potential confounders in the results. CCI 0 vs >0 and ACS cohort 3 1.93 (1.67-2.24), I2=94% Exclusion of Radovanovic 2014 reduced I2 to 57%. 2 2.18 (2.08-2.28), I2=57%. Radovanovic was a large prospective study with significant number of patients (1091) lost to follow up and no adjustment of potential confounders. CCI 0-1 vs >1 and ACS cohort 2 2.26 (1.23-4.16), I2=98% Heterogeneity explored but no leave on out analysis because of 2 studies.  
  Radovanovic was a large prospective study with significant number of patients (1091) lost to follow up and no adjustment of potential confounders. 
 CCI 0-2 vs >2 and ACS cohort 3 2.52 (1.58-4.04), I2=99% Exclusion of Huang 2015 reduced I2 to 39% 2 2.04 (1.83-2.25), I2=39% Huang 2015 was a large retrospective study which adjusted for potential confounders in results. Incremental increase in CCI and PCI cohort 4 1.21 (1.12-1.31), I2=71% Exclusion of Singh 2011 reduced I2to 55%. 3 1.28 (1.14-1.42), I2=55% Singh 2011 is a small prospective study with relatively large loss to follow up and no adjustment for potential confounders. CCI 0-2 vs >2 and CVA cohort 3 3.80 (1.20-12.01), I2=84% Exclusion of no single study reduced I2<75%.   Bar 2011was a small study with unclear method of ascertainment of outcomes and unclear lost to follow up.Goldstein 2004 is a relatively larger sample size reporting mortality at 1 year and also accounted for potential confunders.Tuttlomondo 2008 
  
 
